Screener
BeyondSpring
BYSIBeyondSpring Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies for patients with high unmet medical needs.
$21.25M-73.0%
Earnings
Next report
Nov 12, 2026 (In 1 week)Revenue estimate$8.8M
EPS estimate-$0.54
Competitors
By market cap
By revenue growth
Profile
BeyondSpring Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies for patients with high unmet medical needs. The company's core value proposition centers on its lead asset, Plinabulin, a selective immunomodulating microtubule-binding agent being developed for multiple indications, including non-small cell lung cancer and the prevention of chemotherapy-induced neutropenia.
Competitive position
BeyondSpring is an early-stage developer with a lead asset in late-stage clinical trials, utilizing a dual-market strategy focused on the U.S. and China.
GeographiesUnited States, China, Australia
Customer segmentsPharmaceutical companies, Medical institutions
Business modelR&D, Licensing, Collaboration
SuppliersContract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Raw material suppliers, Academic research institutions
CustomersHospitals, Cancer treatment centers, Specialty pharmaceutical distributors, Strategic licensing partners
CountryUnited States of America
Listed2017
Employees36.0
CEOQiu Min
SectorHealthcare
IndustryBiotechnology
Websitebeyondspringpharma.com
FilingsSEC EDGAR
FAQ
- What is BeyondSpring's market cap?
- BeyondSpring (BYSI) has a market capitalization of $21.2M and trades on NASDAQ.
- Who are BeyondSpring's competitors?
- BeyondSpring's key competitors include Amgen Inc., Spero Therapeutics, Inc. Common Stock, Pliant Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does BeyondSpring partner with?
- BeyondSpring's notable partners include Jiangsu Hengrui Pharmaceuticals Co., Ltd., Eli Lilly and Company, Eisai Co., Ltd., and others.
- What subsidiaries does BeyondSpring have?
- BeyondSpring's subsidiaries include SEED Therapeutics Inc., Wanchunbulin, BeyondSpring (HK) Limited.
- Where is BeyondSpring headquartered?
- BeyondSpring is headquartered in United States of America and employs approximately 36 people. It has been publicly traded since 2017.